COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in-line and launch brands to meet the new reality of customer and business needs during the ongoing pandemic.
This webinar will cover the actions that pharmaceutical commercial teams can take now to stay on track with 2020 goals and to plan for 2021. Pharmaceutical and biotech commercialization teams will hear about trends in the marketplace during the last few months of marketing, medical affairs, market access strategy and customer communication during COVID-19. We will discuss the choices teams have made and the rationale for different approaches. Whether you are seeking to re-start pharmaceutical commercialization or planning for a new launch, the short and long-term planning guidance discussed will be of value.
Beth Schurman, Partner, Herspiegel Consulting
Beth Schurman has helped to grow Herspiegel Consulting during the last 12 years into a world-class firm helping clients with commercial strategy, innovation and execution. She has been involved in new product commercialization and brand optimization across oncology, CNS, metabolic disease, dermatology and women’s and men’s health from rare disease to blockbuster brands. Prior to Herspiegel Consulting, Schurman worked on the client side in marketing roles at Bristol-Myers Squibb and Novo Nordisk.Message Presenter
Brent Herspiegel, President, Herspiegel Consulting
Brent Herspiegel is the Founder and President of Herspiegel Consulting LLC. As a 20-year pharmaceutical industry veteran, Herspiegel brings his substantial global consulting experience and client-side expertise to all projects. With his passion for innovative marketing and strategic planning, Herspiegel has successfully developed Herspiegel Consulting into a trusted partner for hundreds of clients. Since founding Herspiegel Consulting in 2007, Herspeigel has pioneered ground-breaking approaches and set new standards to help clients succeed, while expanding the firm’s core services to address the unique needs of clients’ US and global brands. Herspeigel developed his expertise in pharmaceutical marketing while working in a variety of new product planning, pre-launch, and in-line marketing and sales positions for Novo Nordisk, Eli Lilly and Esprit Pharma (acquired by Allergan). He recognized that many clients’ needs would be best served by uniting exceptional marketing strategy and tactical implementation with a rigorous analytical mindset and approach typical of a consultancy. Herspeigel founded Herspiegel Consulting in an effort to uniquely satisfy those needs in the marketplace.Message Presenter
Who Should Attend?
Director and Senior Level professionals from biopharmaceutical companies working within: Pharmaceutical and Biotech Commercial Leaders of Marketing, Market Access, Medical Affairs and Commercial Operations teams. Omnichannel, brand and market shaping leaders. Director, VP and C-Suite level executives.
What You Will Learn
Join this webinar to learn about:
- Key healthcare environmental changes impacting customer engagement
- Critical areas of consideration for pharmaceutical commercial brand teams
- Re-start implications for in-line brands
- Drug launch planning implications
- Scenario-based planning for the short, medium and long-term
Herspiegel Consulting specializes in pharmaceutical and biotech commercialization helping clients in with strategy through execution in five core service areas of new product planning, marketing, launch readiness, medical affairs, and market access. Herspiegel Consulting offers integrative, tailored consulting services to meet your brand and business needs. Our diverse team brings experience from over 65 product launches, strategy and innovation leadership, and executional support for start-up to large pharma clients. We have experience across a wide variety of therapeutic areas including oncology, rare disease, metabolic disease, CNS, women’s health, and others.